胶质母细胞瘤的免疫疗法：现状、挑战和未来展望。

IF 21.8 1区医学 Q1 IMMUNOLOGY

Cellular &Molecular Immunology Pub Date : 2024-10-15 DOI:10.1038/s41423-024-01226-x

Yang Liu, Fei Zhou, Heba Ali, Justin D. Lathia, Peiwen Chen

{"title":"胶质母细胞瘤的免疫疗法：现状、挑战和未来展望。","authors":"Yang Liu, Fei Zhou, Heba Ali, Justin D. Lathia, Peiwen Chen","doi":"10.1038/s41423-024-01226-x","DOIUrl":null,"url":null,"abstract":"Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard of care offers minimal clinical benefit, and most GBM patients experience tumor recurrence after treatment. In recent years, significant advancements have been made in the development of novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance in many advanced cancers. However, the benefit of immune-based treatments in GBM is limited because of the unique brain immune profiles, GBM cell heterogeneity, and immunosuppressive tumor microenvironment. In this review, we present a detailed overview of current immunotherapeutic strategies and discuss the challenges and potential molecular mechanisms underlying immunotherapy resistance in GBM. Furthermore, we provide an in-depth discussion regarding the strategies that can overcome immunotherapy resistance in GBM, which will likely require combination therapies.","PeriodicalId":9950,"journal":{"name":"Cellular &Molecular Immunology","volume":"21 12","pages":"1354-1375"},"PeriodicalIF":21.8000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41423-024-01226-x.pdf","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy for glioblastoma: current state, challenges, and future perspectives\",\"authors\":\"Yang Liu, Fei Zhou, Heba Ali, Justin D. Lathia, Peiwen Chen\",\"doi\":\"10.1038/s41423-024-01226-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard of care offers minimal clinical benefit, and most GBM patients experience tumor recurrence after treatment. In recent years, significant advancements have been made in the development of novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance in many advanced cancers. However, the benefit of immune-based treatments in GBM is limited because of the unique brain immune profiles, GBM cell heterogeneity, and immunosuppressive tumor microenvironment. In this review, we present a detailed overview of current immunotherapeutic strategies and discuss the challenges and potential molecular mechanisms underlying immunotherapy resistance in GBM. Furthermore, we provide an in-depth discussion regarding the strategies that can overcome immunotherapy resistance in GBM, which will likely require combination therapies.\",\"PeriodicalId\":9950,\"journal\":{\"name\":\"Cellular &Molecular Immunology\",\"volume\":\"21 12\",\"pages\":\"1354-1375\"},\"PeriodicalIF\":21.8000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/s41423-024-01226-x.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cellular &Molecular Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41423-024-01226-x\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular &Molecular Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41423-024-01226-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胶质母细胞瘤（GBM）是一种侵袭性和致命性的成人脑肿瘤。标准疗法的临床疗效甚微，大多数 GBM 患者在治疗后肿瘤复发。近年来，新型免疫疗法或其他治疗策略的开发取得了重大进展，可以克服许多晚期癌症的免疫疗法耐药性。然而，由于独特的脑免疫特征、GBM 细胞异质性和免疫抑制性肿瘤微环境，基于免疫的治疗在 GBM 中的获益有限。在这篇综述中，我们详细概述了当前的免疫治疗策略，并讨论了 GBM 免疫治疗耐药所面临的挑战和潜在的分子机制。此外，我们还深入探讨了克服 GBM 免疫治疗耐药性的策略，这很可能需要联合疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Immunotherapy for glioblastoma: current state, challenges, and future perspectives

查看原文本刊更多论文

Immunotherapy for glioblastoma: current state, challenges, and future perspectives

Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard of care offers minimal clinical benefit, and most GBM patients experience tumor recurrence after treatment. In recent years, significant advancements have been made in the development of novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance in many advanced cancers. However, the benefit of immune-based treatments in GBM is limited because of the unique brain immune profiles, GBM cell heterogeneity, and immunosuppressive tumor microenvironment. In this review, we present a detailed overview of current immunotherapeutic strategies and discuss the challenges and potential molecular mechanisms underlying immunotherapy resistance in GBM. Furthermore, we provide an in-depth discussion regarding the strategies that can overcome immunotherapy resistance in GBM, which will likely require combination therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cellular &Molecular Immunology 医学-免疫学

CiteScore

31.20

自引率

1.20%

发文量

903

审稿时长

1 months

期刊介绍： Cellular & Molecular Immunology, a monthly journal from the Chinese Society of Immunology and the University of Science and Technology of China, serves as a comprehensive platform covering both basic immunology research and clinical applications. The journal publishes a variety of article types, including Articles, Review Articles, Mini Reviews, and Short Communications, focusing on diverse aspects of cellular and molecular immunology.